Get the Stockscreener App
75.45
0.87%
0.65
After Hours:
75.45
Incyte Corp Stock (INCY) Latest News
Glenmede Trust Co. NA Trims Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Massachusetts Financial Services Co. MA Invests $4.74 Million in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Announces Updated Presentation Time for Upcoming Investor Conference - Yahoo Finance
INCY (Incyte) Free Cash Flow per Share : $0.17 (TTM As of Sep. 2024) - GuruFocus.com
Commerce Bank Buys New Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
PNC Financial Services Group Inc. Purchases 9,083 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: pipeline progress faces patent cliff pressure - Investing.com
INCY (Incyte) Long-Term Debt & Capital Lease Obligation : $28 Mil (As of Sep. 2024) - GuruFocus.com
Incyte shares target lifted, buy rating on povorcitinib sales outlook - Investing.com
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting - Yahoo Finance
Incyte : Bull market turns 8historical facts and figures - Marketscreener.com
Analysts Set Incyte Co. (NASDAQ:INCY) Price Target at $77.16 - MarketBeat
Intech Investment Management LLC Decreases Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Banco Santander S.A. - MarketBeat
Cypress Capital Group Invests $971,000 in Incyte Co. (NASDAQ:INCY) - MarketBeat
Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock - Insider Monkey
Incyte Co. (NASDAQ:INCY) Stock Position Lessened by Empowered Funds LLC - MarketBeat
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
What Are Wall Street Analysts' Target Price For Incyte Stock? - Barchart
What Are Wall Street Analysts' Target Price for Incyte Stock? - Inkl
Big Moves: November 19, 2024 - substack.com
Merck (MRK) Eyes Incyte (INCY) for Possible Acquisition - Value the Markets
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
U.S. Indexes Ended Tuesday Mixed As Super Micro Computer Led, Incyte Lagged - Barron's
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. - Yahoo! Voices
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - AOL
BMO keeps Incyte stock at underperform, price target at $52 - Investing.com
Incyte (NASDAQ:INCY) Shares Gap DownHere's Why - MarketBeat
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Yahoo Finance
Merck ‘linked’ to takeover bid for Incyte, Sky News says - TipRanks
Incyte seesaws on report of potential Merck takeover interest (NASDAQ:INCY) - Seeking Alpha
What's Going On With Incyte Shares Tuesday? - Benzinga
Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock. - MSN
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Yahoo Finance
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Incyte Faces Challenges but Remains Focused on Strategic Growth - Yahoo Finance
Incyte sinks on setback for drugs acquired in $750M buyout - BioPharma Dive
Incyte's (INCY) "Neutral" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Incyte price target lowered to $86 from $90 at BofA - TipRanks
RBC maintains sector perform on Incyte shares, cuts target following '262 pause - Investing.com
One Paused, One Dropped: Incyte’s Skin Drug Acquisitions Hit Problems - Citeline News & Insights
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble - BioSpace
Incyte culls one Escient-acquired dermatology programme, pauses another - FirstWord Pharma
After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more - Investing.com
Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP - TipRanks
Incyte (INCY) will pause enrollment in ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria - StreetInsider.com
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs - Yahoo Finance
Dr. Pimple Popper gets personal with eczema in Incyte’s Moments of Clarity push - MM+M Online
Seizert Capital Partners LLC Has $6.24 Million Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects - Insider Monkey
Incyte Co. (NASDAQ:INCY) Shares Purchased by Mizuho Securities USA LLC - MarketBeat
Incyte Co. (NASDAQ:INCY) Shares Sold by Principal Financial Group Inc. - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte price target raised to $80 from $72 at RBC Capital - TipRanks
1.35%
3.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):